New York, Jan 7, 2026, 17:32 EST — After-hours
- Eli Lilly agreed to buy Ventyx Biosciences for $14 a share in cash, valuing the biotech at about $1.2 billion
- Ventyx shares closed up about 37% at $13.81; Lilly shares rose about 4%
- Investors are watching the proxy timeline and Lilly’s next earnings call for detail on the deal and 2026 plans
Shares of Ventyx Biosciences (VTYX.O) jumped on Wednesday after Eli Lilly (LLY.N) agreed to buy the San Diego-based biotech in a $14-per-share all-cash deal. Ventyx closed up about 37% at $13.81 and was last at $13.73 in after-hours trading, still shy of the offer price. 1
For Lilly, the deal is a small bolt-on at a moment when the drugmaker is flush from sales of its diabetes and weight-loss medicines. Cantor Fitzgerald analyst Carter Gould called the price tag “borderline immaterial” for Lilly and said the company is taking shots on assets that could scale inside its cardiometabolic business. 2
Lilly and Ventyx said the transaction is not subject to financing and is expected to close in the first half of 2026, pending Ventyx shareholder approval and other customary conditions. Lilly research chief Daniel Skovronsky said “there is increasing evidence that inflammation is a key driver of many chronic diseases,” while Ventyx CEO Raju Mohan said Lilly was “an ideal strategic partner.” 3
Ventyx has been developing pill-form treatments aimed at inflammatory diseases, including targets linked to immune response. The company’s work includes drugs aimed at NLRP3, a protein complex tied to inflammation, and the deal lands as large drugmakers — including Roche and Novo Nordisk — look for new ways to compete in immunology and related areas. 4
The stock price tells traders there is still some uncertainty. In merger terms, the “deal spread” — the gap between the offer and where the stock trades — reflects the market’s estimate of how clean and how fast the closing will be.
Lilly shares rose about 4% to $1,108.09, suggesting equity investors are comfortable with the size of the check and the strategic fit.
But cash deals can still wobble. A slower timetable, tougher regulatory questions, or shareholder pushback can widen the spread, and any hint of delays tends to show up first in the target’s trading.
Next up, investors will watch for Ventyx’s proxy filings and the schedule for the shareholder vote. Lilly’s next major checkpoint is its Q4 2025 earnings call on Feb. 4, when analysts are likely to press management on how the acquisition fits into 2026 priorities. 5
